Literature DB >> 11875230

Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996.

Ramin Mojtabai1, Janet Lavelle, P Joseph Gibson, Nancy L Sohler, Thomas J Craig, Gabrielle A Carlson, Evelyn J Bromet.   

Abstract

The authors examined gaps in the use of antipsychotic medications during the one-year period after discharge in an epidemiological sample of 189 first-admission patients with schizophrenia between July 1989 and January 1996. Sixty-three percent of the patients had one or more such gaps, and 51 percent had gaps of 30 days or longer, with an average total time off medication of about seven months. Most gaps occurred soon after discharge, and 73 percent were initiated by the patient. These data, which were obtained before the widespread use of atypical antipsychotic agents, provide a benchmark against which to examine the impact of the newer medications on adherence and continuity of treatment in the critical early stages of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11875230     DOI: 10.1176/appi.ps.53.3.337

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  12 in total

1.  Implementing performance improvement and measuring psychiatric care quality.

Authors:  Geetha Jayaram
Journal:  Psychiatry (Edgmont)       Date:  2007-05

2.  One year outcome in first episode schizophrenia. Predictors of relapse.

Authors:  Alp Uçok; Aslihan Polat; Sibel Cakir; Aysun Genç
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-18       Impact factor: 5.270

3.  Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia.

Authors:  Susan dosReis; Elizabeth Johnson; Donald Steinwachs; Charles Rohde; Elizabeth A Skinner; Maureen Fahey; Anthony F Lehman
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

4.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  Refill non-adherence to repeat prescriptions leads to treatment gaps or to high extra costs.

Authors:  Kristin Krigsman; Arne Melander; Anders Carlsten; Anders Ekedahl; J Lars Nilsson
Journal:  Pharm World Sci       Date:  2007-02

6.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.

Authors:  Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis
Journal:  Schizophr Bull       Date:  2015-03-05       Impact factor: 9.306

7.  Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study.

Authors:  Alkomiet Hasan; Claus Wolff-Menzler; Sebastian Pfeiffer; Peter Falkai; Elif Weidinger; Andrea Jobst; Imke Hoell; Berend Malchow; Peyman Yeganeh-Doost; Wolfgang Strube; Silke Quast; Norbert Müller; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-26       Impact factor: 5.270

8.  A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia.

Authors:  Rachel Miller; Geoffrey Ream; Joanne McCormack; Handan Gunduz-Bruce; Serge Sevy; Delbert Robinson
Journal:  Schizophr Res       Date:  2009-05-28       Impact factor: 4.939

9.  Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.

Authors:  Ramin Mojtabai; Laura Fochtmann; Su-Wei Chang; Roman Kotov; Thomas J Craig; Evelyn Bromet
Journal:  Schizophr Bull       Date:  2009-06-08       Impact factor: 9.306

10.  Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.

Authors:  Yoshiteru Takekita; Yosuke Koshikawa; Chiara Fabbri; Shiho Sakai; Naotaka Sunada; Ai Onohara; Keiichiro Nishida; Masafumi Yoshimura; Masaki Kato; Alessandro Serretti; Toshihiko Kinoshita
Journal:  BMC Psychiatry       Date:  2016-05-29       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.